50841-47-9

Basic information

• Product Name: 3,5-Dibenzyloxyphenyloxirane
• Synonyms: [3,5-Bis(benzyloxy)phenyl]oxirane;[3,5-Bis(phenylmethoxy)phenyl]oxirane;3,5-Dibenzyloxyphenyloxirane
• CAS NO: 50841-47-9
• Molecular Formula: C₂₂H₂₀O₃
• Molecular Weight: 332.39
• Product Categories: Aromatics;Heterocycles
• Mol File: 50841-47-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 501.5°C at 760 mmHg
• Flash Point: 172.3°C
• Appearance: /
• Density: 1.196g/cm³
• Vapor Pressure: 1.07E-09mmHg at 25°C
• Refractive Index: 1.619
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 3,5-Dibenzyloxyphenyloxirane(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dibenzyloxyphenyloxirane(50841-47-9)
• EPA Substance Registry System: 3,5-Dibenzyloxyphenyloxirane(50841-47-9)

Safety Data

• Hazardous Substances Data: 50841-47-9(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Syrup

Uses

An intermediate for the preparation of Terbutaline

InChI:InChI=1/C22H20O3/c1-3-7-17(8-4-1)14-23-20-11-19(22-16-25-22)12-21(13-20)24-15-18-9-5-2-6-10-18/h1-13,22H,14-16H2

Upstream product

• 14615-72-6 3,5-dibenzyloxybenzaldehyde 
• 1030268-21-3 trimethylsulfonium iodide 
• 28924-18-7 2-bromo-1-[3,5-bis(phenylmethoxy)phenyl]ethanone 
• 2181-42-2 trimethylsulphonium iodide 

Downstream Products

• 96564-53-3 3-<2-(3,5-dibenzyloxyphenyl)-2-hydroxy-ethylamino>-butyric acid 
• 96564-52-2 3-<2-(3,5-dibenzyloxyphenyl)-2-hydroxy-ethylamino>-3-methyl-butyric acid 
• 96564-50-0 2-<2-(3,5-dibenzyloxyphenyl)-2-hydroxy-ethylamino>-2-methyl-propionic acid 
• 41852-55-5 α-(aminomethyl)-3,5-bis(benzyloxy)benzyl alcohol 
• 96564-51-1 2-<2-(3,5-dibenzyloxyphenyl)-2-hydroxy-ethylamino>-propionic acid 
• 52536-56-8 5-[1-hydroxy-2-(4-methyl-piperazin-1-yl)-ethyl]-benzene-1,3-diol 
• 96564-78-2 isobutyl 3-<2-(3,5-dibenzyloxyphenyl)-2-hydroxy-ethylamino>-butyrate 
• 96564-77-1 butyl 3-<2-(3,5-dibenzyloxyphenyl)-2-hydroxy-ethylamino>-butyrate 
• 96564-75-9 3-<2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino>-butyric acid sulfate 
• 96564-80-6 butyl 3-<2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino>-butyrate, sulfate 
• 96564-82-8 isobutyl 3-<2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino>-butyrate, sulfate 
• 96564-74-8 3-<2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino>-butyric acid 
• 96564-66-8 methyl 3-<2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino>-butyrateI 
• 96564-54-4 methyl 2-<2-(3,5-dibenzyloxyphenyl)-2-hydroxy-ethylamino>-2-methyl-propioniate 

Relevant articles and documents

Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylethylamino)- 1-hydroxyethyl)-benzene-1,3-diol ([18F]FEFE) for the in vivo visualisation and quantification of the β2-adrenergic receptor status in lung

The 18F-labeled β2-adrenergic receptor ligand (R,R)(S,S) 5-(2-(2-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylethylamino)- 1-hydroxyethyl)-benzene-1,3-diol, a derivative of the original highly selective racemic fenoterol, was synthesized in an overall radiochemical yield of 20% after 65 min with a radiochemical purity higher than 98%. The specific activity was in the range of 50-60 GBq/μmol. In vitro testing of the non-radioactive fluorinated fenoterol derivative with isolated guinea pig trachea was conducted to obtain an IC50 value of 60 nM. Preliminary ex vivo organ distribution and in vivo experiments with positron emission tomography (PET) on guinea pigs were performed to study the biodistribution as well as the displacement of the radiotracer to prove specific binding to the β2-receptor.

SINTESI E STUDIO FARMACOLOGICO DI DERIVATI DELL'ORCIPRENALINA E DEL SALBUTAMOLO

The effect of replacing the basic aliphatic residue of orciprenaline and salbutamol with: a) a heterocyclic amine; b) a basic residue containing a phenylcyclohexane radical has been studied.The synthesis of the compounds is outlined.They were tested in vitro for relaxation of histamine-induced spasm of tracheal chains and on the isolated Langendorff heart, and in vivo according to the Konzett and Roessler technique and for their action on the cardiovascular system.In all tests the new derivatives were less active than the reference substances; the only exception was (A) where R = 4-phenylpiperidine (M.G.6604), which was almost as active as orciprenaline in the Konzett and Roessler test, had one third of its activity on isolated trachea and showed absolutely no influence on heart rate in vitro or in vivo.Its effect was not inhibited by β-blocking agents; it therefore showed as antihistaminic profile.